Literature DB >> 25770211

Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.

Maud Kamal1, Florence Gbahou1, Jean-Luc Guillaume1, Avais M Daulat1, Abla Benleulmi-Chaachoua1, Marine Luka1, Patty Chen1, Dina Kalbasi Anaraki1, Marc Baroncini2, Clotilde Mannoury la Cour3, Mark J Millan3, Vincent Prevot2, Philippe Delagrange3, Ralf Jockers4.   

Abstract

Inasmuch as the neurohormone melatonin is synthetically derived from serotonin (5-HT), a close interrelationship between both has long been suspected. The present study reveals a hitherto unrecognized cross-talk mediated via physical association of melatonin MT2 and 5-HT2C receptors into functional heteromers. This is of particular interest in light of the "synergistic" melatonin agonist/5-HT2C antagonist profile of the novel antidepressant agomelatine. A suite of co-immunoprecipitation, bioluminescence resonance energy transfer, and pharmacological techniques was exploited to demonstrate formation of functional MT2 and 5-HT2C receptor heteromers both in transfected cells and in human cortex and hippocampus. MT2/5-HT2C heteromers amplified the 5-HT-mediated Gq/phospholipase C response and triggered melatonin-induced unidirectional transactivation of the 5-HT2C protomer of MT2/5-HT2C heteromers. Pharmacological studies revealed distinct functional properties for agomelatine, which shows "biased signaling." These observations demonstrate the existence of functionally unique MT2/5-HT2C heteromers and suggest that the antidepressant agomelatine has a distinctive profile at these sites potentially involved in its therapeutic effects on major depression and generalized anxiety disorder. Finally, MT2/5-HT2C heteromers provide a new strategy for the discovery of novel agents for the treatment of psychiatric disorders.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cell Signaling; Depression; G Protein-coupled Receptor (GPCR); GPCR; Heteromerization; Melatonin; Molecular Pharmacology; Serotonin

Mesh:

Substances:

Year:  2015        PMID: 25770211      PMCID: PMC4416857          DOI: 10.1074/jbc.M114.559542

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain.

Authors:  M Pasqualetti; M Ori; M Castagna; D Marazziti; G B Cassano; I Nardi
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET.

Authors:  Pascale G Charest; Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

3.  Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.

Authors:  Egemen Savaskan; Mohammed A Ayoub; Rivka Ravid; Debora Angeloni; Franco Fraschini; Fides Meier; Anne Eckert; Franz Müller-Spahn; Ralf Jockers
Journal:  J Pineal Res       Date:  2005-01       Impact factor: 13.007

Review 4.  G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Authors:  Graeme Milligan
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

5.  Melatonin inhibits in vitro serotonergic phase shifts of the suprachiasmatic circadian clock.

Authors:  R A Prosser
Journal:  Brain Res       Date:  1999-02-13       Impact factor: 3.252

6.  Inhibition of serotonin 5-hydroxytryptamine2c receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein.

Authors:  Katharine Herrick-Davis; Ellinor Grinde; Timothy J Harrigan; Joseph E Mazurkiewicz
Journal:  J Biol Chem       Date:  2005-09-29       Impact factor: 5.157

7.  Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3'-5'-monophosphate pathway.

Authors:  L Petit; I Lacroix; P de Coppet; A D Strosberg; R Jockers
Journal:  Biochem Pharmacol       Date:  1999-08-15       Impact factor: 5.858

8.  Constitutive dimerization of human serotonin 5-HT4 receptors in living cells.

Authors:  Magali Berthouze; Mohammed Ayoub; Olivier Russo; Lucie Rivail; Sames Sicsic; Rodolphe Fischmeister; Isabelle Berque-Bestel; Ralf Jockers; Frank Lezoualc'h
Journal:  FEBS Lett       Date:  2005-06-06       Impact factor: 4.124

9.  Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

Authors:  S W Ying; B Rusak; P Delagrange; E Mocaer; P Renard; B Guardiola-Lemaitre
Journal:  Eur J Pharmacol       Date:  1996-01-18       Impact factor: 4.432

10.  The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

Authors:  M J Millan; A Gobert; F Lejeune; A Dekeyne; A Newman-Tancredi; V Pasteau; J-M Rivet; D Cussac
Journal:  J Pharmacol Exp Ther       Date:  2003-05-15       Impact factor: 4.030

View more
  34 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 2.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

Review 3.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

4.  Systematic review of melatonin levels in individuals with complete cervical spinal cord injury.

Authors:  Alexander Whelan; Mary Halpine; Sean D Christie; Sonja A McVeigh
Journal:  J Spinal Cord Med       Date:  2018-08-22       Impact factor: 1.985

Review 5.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

Review 6.  Melatonin transport into mitochondria.

Authors:  Juan C Mayo; Rosa M Sainz; Pedro González-Menéndez; David Hevia; Rafael Cernuda-Cernuda
Journal:  Cell Mol Life Sci       Date:  2017-08-21       Impact factor: 9.261

Review 7.  Arrestin recruitment and signaling by G protein-coupled receptor heteromers.

Authors:  Kendall L Mores; Robert J Cassell; Richard M van Rijn
Journal:  Neuropharmacology       Date:  2018-11-09       Impact factor: 5.250

8.  Design and validation of the first cell-impermeant melatonin receptor agonist.

Authors:  Florence Gbahou; Erika Cecon; Guillaume Viault; Romain Gerbier; Frederic Jean-Alphonse; Angeliki Karamitri; Gérald Guillaumet; Philippe Delagrange; Robert M Friedlander; Jean-Pierre Vilardaga; Franck Suzenet; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

9.  Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.

Authors:  Dilip K Tosh; Antonella Ciancetta; Eugene Warnick; Steven Crane; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2016-12-09       Impact factor: 7.446

10.  Endogenous Serotonin 5-HT2A and 5-HT2C Receptors Associate in the Medial Prefrontal Cortex.

Authors:  Amanda E Price; Dennis J Sholler; Sonja J Stutz; Noelle C Anastasio; Kathryn A Cunningham
Journal:  ACS Chem Neurosci       Date:  2019-03-18       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.